Prof Herbie Newell Abstract DCW 2022

Title:  Update on the development of the cysteamine prodrug CF10

Abstract:  CF10 is a cysteamine prodrug designed to overcome the limitations encountered with cysteamine therapy and hence improve cystinosis control.  With funding from the UK Medical Research Council regulatory safety studies required for the preclinical development of CF10 are approaching completion.  In collaboration with Dr Jennifer Hollywood and Professor Alan Davidson, University of Auckland New Zealand, the activity of CF10 in a rat model of cystinosis is being investigated and in parallel support for the clinical development of CF10 is being accessed, i.e. for synthesis of the API to GMP standards, formulation and clinical trials.